Monoclonal Antibody Infusions

A treatment option for COVID-19, now available at ACMH.

Monoclonal antibodies are among the most promising treatments for mild to moderate COVID-19, the disease caused by the novel coronavirus SARS-CoV-2. ACMH is now offering area providers the option to order a monoclonal treatment for qualifying patients.

ACMH is pleased to be among the health care organizations in Pennsylvania offering monoclonal antibody treatment, which is authorized by the FDA for emergency use in the treatment of COVID-19.

A doctor's order is required to receive treatment. Contact your physician to see if you qualify, and your provider will schedule your appointment at the outpatient infusion center located in the ACMH Health and Wellness Education Pavilion, 79 Glade Drive, Kittanning, PA.

Monoclonal Antibodies

Antibodies are proteins made by your body's immune system that fight off infections, including infections caused by viruses. Your body can remember how to make antibodies if you are exposed to the same germ again.

Monoclonal antibodies are just like your body's antibodies but selected for their strong ability to resist the virus. They are produced like a medication and help your body fight illness. In 2020, the Food and Drug Administration issued an emergency use authorization to permit monoclonal antibodies as a treatment option for COVID-19.

 

THE MONOCLONAL ANTIBODY TREATMENT PROCESS

After entering your body, monoclonal antibodies look for and attach to the spike protein that sticks out of the coronavirus that causes COVID-19.

When monoclonal antibodies attach to the spike protein, they can block the virus's ability to enter cells — and slow down the infection.

In 2020, the FDA authorized several different monoclonal antibodies to treat COVID-19. 

 

THE EFFECTIVENESS OF MONOCLONAL ANTIBODY TREATMENT

According to a study from the New England Journal of Medicine, early clinical data show that monoclonal antibodies can successfully reduce COVID-19 hospitalization rates. Clinical trials have shown that these treatments can decrease hospitalizations and emergency department visits. They can also reduce the amount of virus found in an infected person's blood.

Health officials continue to monitor the safety and effectiveness of the treatments, and clinical trials are ongoing.

Monoclonal Antibody Treatment at ACMH

Eligibility for monoclonal antibody treatment:

Anyone who tested positive for COVID-19, has had symptoms for 10 days or less, and one of the following:

  • Be at least 65 years old
  • Have a BMI of more than 25 kg/m2, or if age 12-17, have BMI above the 85th percentile for their age and gender based on CDC growth charts
  • Currently Pregnant
  • Chronic Lung Disease (COPD, asthma, pulmonary hypertension, cystic fibrosis)
  • Have a medical condition, including:
    • Chronic kidney disease
    • Cardiovascular disease (including congenital heart disease, hypertension)
    • Diabetes
    • Down syndrome
    • Dementia
    • Liver disease
    • Chronic lung disease
    • Sickle cell disease
    • Immunosuppressive disease or immunosuppressive treatment
  • Current or former smoker
  • History of stroke or cerebrovascular disease
  • Current or history of substance abuse
  • Neurodevelopmental disorders or other conditions that confer medical complexity
  • Have a medical-related technological dependence (e.g., tracheostomy, gastrostomy)

Note: Monoclonal antibody treatment needs to be given within 10 days of the start of symptoms. 

 

Contact your doctor to be evaluated and learn if you qualify for monoclonal antibody treatment at ACMH.

A doctor’s order is required to receive treatment. Once evaluated, your provider will schedule the appointment with the infusion center, and provide you with a date and time for you to come in for your treatment. Outpatient antibody infusions are administered at the ACMH Health and Wellness Education Pavilion located at 79 Glade Drive, Kittanning, PA.

 

More Information

Click HERE to read a Fact Sheet for Patients, Parents and Caregivers on the Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab for Coronavirus Disease 2019 (COVID-19)

PHYSICIAN PORTAL

Registration and scheduling information for providers.
 

ENTER HERE